No Data
Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.
Track the entire lifecycle of the main sector.
GF SEC: Maintains the "Buy" rating for Hutchmed (China) with a fair value of HKD 41.35.
GF SEC released a research report stating that it maintains the "Buy" rating for Hutchmed (China) (00013), expecting the attributable Net income for 2024-2026 to be 0.005, 0.02, and 0.074 billion USD respectively, and through the DCF method, the company's fair value is determined to be HKD 41.35 per share (1 USD = 7.78 HKD). The company's R&D, commercialization, and overseas expansion capabilities have been preliminarily validated, and there is a sufficient pipeline of differentiated innovations. As various products gradually enter the harvest period, GF SEC's main points are as follows: Event 1: The company announced on January 2, 2025, the combination therapy of Saviorinib and Osimertinib for the treatment of patients with.
Shanghai Pharmaceuticals Holding and Yunnan Baiyao Renew Sales Agreement for 2025
SH PHARMA (601607.SH): Isosorbide dinitrate injection has passed the consistency evaluation of generic drugs.
On January 2, Gelonghui reported that SH PHARMA (601607.SH) announced that its wholly-owned subsidiary, Shanghai SH PHARMA First Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as 'SH PHARMA First Biochemical'), received the 'Pharmaceutical Supplement Application Approval Notice' (Notice No: 2024B05558) issued by the National Medical Products Administration regarding Isosorbide Dinitrate Injection (hereinafter referred to as 'the Pharmaceutical'), which has passed the consistency evaluation of quality and efficacy for generic drugs.
Hutchmed Projects Gain of $477 Million From Hutchison Pharmaceutical Stake Disposal
Hutchmed (China) plans to sell a total of 45% equity in Shanghai Hutchmed.
Hutchmed (China) (00013) announced that on December 31, 2024, the seller, Shanghai Hutchmed Pharmaceutical Investment (Hong Kong) Limited (a wholly-owned subsidiary of the company), entered into a share purchase agreement with Jinpu Jianfu for the sale of shares pending purchase at a total purchase price of RMB 3.483 billion (approximately USD 0.473 billion), representing 35% of the equity of Shanghai Hutchmed; and entered into a share purchase agreement with SH PHARMA for the sale of shares pending purchase at a total purchase price of RMB 0.995 billion (approximately USD 0.135 billion), representing 10% of the equity of Shanghai Hutchmed.
Return Trends At Shanghai Pharmaceuticals Holding (SHSE:601607) Aren't Appealing
No Data
